Enquiry form
General enquiries:
+44 (0)207 935 4444
Book a consultation:
+44 (0)207 616 7693
Self-pay enquiry:
+44 (0)203 219 3315
05 September 2019
In the media

The London Clinic is one of a small number of hospitals to offer adult patients with diffuse large B-cell lymphoma – an aggressive form of blood cancer - a new, cutting-edge form of immunotherapy called CAR T-cell therapy.

Graphic showing a chimeric antigen receptor (c. Middle East Medical Portal)


Professor John Gribben, Consultant Haematologist, explains why CAR T-cell therapy has the potential to revolutionise cancer treatment in his interview with the Middle-East Medical Portal.

“I am excited by CAR T-cell therapy’s ability to adapt the patient’s own immune system to fight cancers,” says Professor Gribben. “This is encouraging because if the patient responds as we hope, we are unlikely to see a late return of the cancer. There are no guarantees, but the fact that there is some uncertainty about the future is still a vastly better scenario than we have ever been able to offer these patients before.”

Read Professor Gribben's interview in full at the Middle East Medical portal.

Further information

Share to Twitter Share to Facebook Share to LinkedIn Share to Google Plus